Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. Prosperini L, Annovazzi P, Capobianco M, Capra R, Buttari F, Gasperini C, Galgani S, Solaro C, Centonze D, Bertolotto A, et al. Mult Scler. 2015 Feb 19. PMID: 25698174. Abstract CommentRecommendBookmarkWatch